Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Glytas M 60mg/500mg Tablet ER

Prescription Icon
Prescription Required

Marketer

Tas Med India Pvt Ltd

Salt Composition

Gliclazide (60mg) + Metformin (500mg)

Overview Glytas M 60mg/500mg Tablet ER

Metformin/glimepiride extended-release tablets (60mg/500mg) are classified as antidiabetic medications. This dual-action formulation treats type 2 diabetes in adults by managing blood glucose levels. Administer this medication with food, consistently at the same time daily for optimal effectiveness. Dosage is determined by your physician and may be adjusted based on your blood sugar response. Continuous use is crucial; discontinuation without medical consultation risks elevated blood sugar, potentially leading to kidney complications, vision loss, neuropathy, and limb amputation. Remember, this medication is part of a comprehensive diabetes management plan encompassing diet, exercise, and weight management as directed by your doctor. Lifestyle choices are vital for diabetes control. Common adverse effects include hypoglycemia (low blood sugar), characterized by sweating, dizziness, headache, and tremors; constipation; and vomiting. Maintain regular mealtimes and carry readily available glucose sources (e.g., sugary snacks, fruit juice) to counteract hypoglycemia. Alcohol consumption should be limited due to its potential to exacerbate low blood sugar. Additional possible side effects include altered taste, nausea, diarrhea, abdominal pain, headache, and upper respiratory infections. Weight gain may occur. This medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Individuals with a history of heart disease should inform their physician before commencing treatment. Pregnant or lactating women should seek medical advice prior to use. Regular blood glucose monitoring is necessary, and your doctor may order blood tests to assess blood cell counts and liver function.

Uses of Glytas M 60mg/500mg Tablet ER

Adult-onset diabetes

Major Benefits of Glytas M 60mg/500mg Tablet ER:

Follow your physician's instructions precisely regarding dosage and treatment length for Glytas M 60mg/500mg Extended-Release Tablets. Ingest the tablets whole; avoid chewing, crushing, or breaking them. Administer this medication with a meal.

Common Side effects of Glytas M 60mg/500mg Tablet ER:

  • Hypoglycemia (low blood glucose level)
  • Headache
  • Dizziness
  • Diarrhea
  • Upper respiratory tract infection
  • Nausea
  • Flatulence
  • Constipation

How to use Glytas M 60mg/500mg Tablet ER:

Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the Glytas M 60mg/500mg Extended-Release tablet whole; avoid chewing, crushing, or fracturing it. Consume this medication with food.

How Glytas M 60mg/500mg Tablet ER works:

Extended-release Glytas M tablets (60mg/500mg) contain gliclazide and metformin, both agents used to manage blood sugar levels.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Glytas M 60mg/500mg Extended-Release tablets with alcohol is not advisable due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Glytas M 60mg/500mg tablets pose a confirmed risk to fetal development and should not be taken during pregnancy. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Always seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Glytas M 60mg/500mg tablets are likely not safe for use while breastfeeding. Available human data indicate potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Glytas M 60mg/500mg Extended-Release tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates Glytas M 60mg/500mg Extended-Release tablet use. Physician consultation is necessary. Regular kidney function monitoring is recommended during treatment.

LiverLiverCAUTION

Patients with liver disease should use Glytas M 60mg/500mg Extended-Release tablets cautiously, as dose modification may be necessary. Individuals with severe liver impairment should avoid this medication. A lower initial dose is typically prescribed for those with mild to moderate liver disease. Physician consultation is recommended.

What if you forget to take Glytas M 60mg/500mg Tablet ER :

Should you forget to take a Glytas M 60mg/500mg Extended-Release tablet, administer it immediately upon remembering. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Glytas M 60mg/500mg Tablet ER

LabelValue
Developing Habits No.
Treatment Category Diabetes Treatment

FAQs on Glytas M 60mg/500mg Tablet ER

Glytas M 60mg/500mg Extended-Release tablets combine gliclazide and metformin to manage type 2 diabetes mellitus in adults. This combination improves blood sugar control when used with diet and exercise. Gliclazide stimulates insulin release from the pancreas, while metformin reduces liver glucose production and enhances insulin sensitivity. It's not suitable for type 1 diabetes.
Glytas M 60mg/500mg ER tablets may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects, including lactic acidosis, are also possible. Prolonged use may result in vitamin B12 deficiency.
Glytas M 60mg/500mg ER Tablets can cause low blood sugar (hypoglycemia), manifesting as nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, anxiety, or shakiness. This risk increases with missed meals, alcohol consumption, excessive exercise, or concurrent use of other antidiabetic medications. Regular blood sugar monitoring is crucial. Carry glucose tablets, honey, or fruit juice for emergencies.
Glytas M 60mg/500mg Tablet ER can cause lactic acidosis, a serious medical emergency characterized by high blood lactic acid levels (also known as MALA, Metformin-associated lactic acidosis). This rare side effect is preventable by avoiding use in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these symptoms, discontinue Glytas M 60mg/500mg Tablet ER immediately and seek medical attention.
Prolonged use of Glytas M 60mg/500mg Tablet ER can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency, if left untreated, may result in anemia, neurological issues such as tingling, numbness in the extremities, weakness, urinary problems, cognitive changes, and ataxia. To mitigate this risk, supplemental vitamin B12 is recommended at least annually by some researchers.
Glytas M 60mg/500mg Tablet ER is contraindicated in patients with known hypersensitivity to its components or excipients, and in those with moderate to severe kidney disease or metabolic acidosis, such as diabetic ketoacidosis.
Combining Glytas M 60mg/500mg ER tablets with alcohol is unsafe. Alcohol can worsen low blood sugar and raise the risk of lactic acidosis.
Glytas M 60mg/500mg Extended-Release tablets combine gliclazide and metformin to manage type 2 diabetes mellitus in adults. This combination improves blood sugar control when used with diet and exercise. Gliclazide stimulates insulin release from the pancreas, while metformin reduces liver glucose production and enhances insulin sensitivity. It's not suitable for type 1 diabetes.
Glytas M 60mg/500mg Extended-Release Tablets may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects, including lactic acidosis, are also possible. Prolonged use may result in vitamin B12 deficiency.
Glytas M 60mg/500mg ER tablets can cause low blood sugar (hypoglycemia), manifesting as nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, anxiety, or shakiness. This risk increases with missed meals, alcohol consumption, excessive exercise, or concurrent use of other diabetes medications. Therefore, regular blood sugar monitoring is crucial. Carry glucose tablets, honey, or fruit juice to treat low blood sugar.
Glytas M 60mg/500mg Tablet ER can cause lactic acidosis, a serious medical emergency resulting from excess blood lactic acid (also known as Metformin-associated lactic acidosis or MALA). This rare side effect is preventable by avoiding use in patients with kidney disease, the elderly, or those consuming excessive alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If experienced, discontinue Glytas M 60mg/500mg Tablet ER and seek immediate medical attention.
Prolonged Glytas M 60mg/500mg Tablet ER use can lead to vitamin B12 deficiency by hindering its stomach absorption. This deficiency, if left untreated, may result in anemia, neurological issues such as tingling, numbness in extremities, weakness, urinary problems, cognitive changes, and ataxia. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Glytas M 60mg/500mg Tablet ER is contraindicated in patients with known allergies to its components or excipients, and in those with moderate to severe kidney disease or metabolic acidosis (including diabetic ketoacidosis).
Combining Glytas M 60mg/500mg ER tablets with alcohol is unsafe. Alcohol can worsen hypoglycemia and raise the risk of lactic acidosis.
Glytas M 60mg/500mg Table...
160
MRP 195
17% off